Inotuzumab Ozogamicin: First Global Approval-Reference-Cited by-同舟云学术

Inotuzumab Ozogamicin: First Global Approval

Published:2017-08-17 Issue:14 Volume:77 Page:1603-1610
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Lamb Yvette N.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/article/10.1007/s40265-017-0802-5/fulltext.html

Reference28 articles.

1. Thota S, Advani A. Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia. Eur J Haematol. 2017;98(5):425–34.

2. Yilmaz M, Richard S, Jabbour E. The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia. Ther Adv Hematol. 2015;6(5):253–61.

3. Pfizer. Besponsa approved in the EU for adult patients with relapsed or refractory B-cell percursor acute lymphoblastic leukemia [media release]. 30 Jun 2017. http://www.pfizer.com/ .

4. Pfizer Limited. Besponsa (inotuzumab ozogamicin) 1 mg powder for concentrate for solution for infusion: summary of product characteristics. 2017. Accessed 21 Jul 2017.

5. Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740–53.

Cited by 152 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acid-sensitive prodrugs; a promising approach for site-specific and targeted drug release;European Journal of Medicinal Chemistry;2024-10

2. Antibody Drug Conjugates for Cancer Therapy: From Metallodrugs to Nature-Inspired Payloads;International Journal of Molecular Sciences;2024-08-08

3. Prediction of Response to FDA-Approved Targeted Therapy and Immunotherapy in Acute Lymphoblastic Leukemia (ALL);Current Treatment Options in Oncology;2024-08-05

4. Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies;MedComm;2024-07-28

5. The chemistry of heterocycles in the 21st century;Russian Chemical Reviews;2024-07